Ferring Pharmaceuticals Shares New Insights on SI-6603
PARSIPPANY, N.J.—Ferring Pharmaceuticals, in collaboration with Seikagaku Corporation, has recently revealed encouraging results from two Phase 3 studies focusing on the investigational drug SI-6603 (condoliase). This treatment is being assessed for its ability to relieve radicular leg pain related to lumbar disc herniation (LDH). The findings presented during the North American Spine Society’s Annual Meeting highlighted remarkable outcomes from studies conducted in the U.S. and Japan. Additionally, the critical results from the U.S. Phase 3 trial have been published in The Spine Journal.
Key Takeaways from the NASS Presentation
The studies employed a double-blind, placebo-controlled design, where patients with LDH received either a single injection of SI-6603 or a control substance—this was a sham in the U.S. study and a placebo in Japan. After 52 weeks of monitoring, significant improvements were observed. Specifically, the U.S. study reported a least squares mean (LSM) difference of -7.5 with a p-value of 0.0263, while the Japanese study recorded an LSM difference of -15.2 with a p-value of 0.001.
Clinical Significance of the Findings
Dr. Kee Kim from the University of California, Davis, highlighted the importance of these findings, saying, "At present, options for treating radicular leg pain caused by lumbar disc herniation mostly revolve around conservative management, which can be limited in effectiveness. The data from these Phase 3 trials strongly positions SI-6603 as a promising treatment for individuals struggling with this tough condition. This could truly transform countless lives."
Safety and Adverse Events Noted
In the U.S. trial, there were notable treatment-emergent adverse events (TEAEs). Spinal MRI abnormalities were reported in 28.1% of participants receiving SI-6603, compared to just 9.2% in the sham group. Additionally, back pain impacted around 19.2% of those on SI-6603 versus 12.6% on the placebo. In the Japanese trial, back pain was the most frequently reported TEAE, occurring in 36.6% of those taking SI-6603 and 33.3% on the placebo.
Analysis of Treatment-Related Adverse Events
Importantly, the U.S. study found no serious adverse events directly attributed to SI-6603, while the Japanese study reported one serious adverse event related to back pain.
Details of the U.S. Phase 3 Trial
The U.S.-based trial, called the Discovery 6603 clinical trial (NCT03607838), was randomized, splitting participants evenly between a SI-6603 injection and a sham, followed by 52 weeks of observation. The primary measure focused on changes from baseline (CFB) in the worst leg pain reported over the previous 24 hours, assessed through the Visual Analogue Scale (VAS). Secondary measures included additional pain evaluations and indicators of quality of life. Encouraging results were noted at Week 13, yet key secondary measures did not achieve significance, highlighting the complexities of assessing treatment effects over time.
Overview of the Japanese Phase 3 Trial
The Japanese trial mirrored this structure with a double-blind, placebo-controlled setup. Participants were given either a dose of SI-6603 (1.25 U) or a placebo, followed by a year of observation. The primary endpoint examined CFB to Week 13 using VAS for assessing leg pain, with a focus on changes up to Week 52.
Understanding Lumbar Disc Herniation
Each year, roughly nine million adults in the U.S. suffer from lumbar disc herniation. This condition typically arises when the inner material of the intervertebral disc shifts, leading to nerve compression and pain. Such issues can disrupt daily activities and have a significant impact on overall quality of life.
About the Investigational Product SI-6603
SI-6603, created with condoliase, aims to relieve radicular leg pain through a single direct injection. It works by alleviating nerve root compression, which is crucial for reducing pain for affected individuals.
Commercial Progress of SI-6603
Seikagaku developed SI-6603 and obtained marketing approval in Japan in early 2018. Since then, it has been marketed under the name HERNICORE 1.25 units for intradiscal injection, primarily through Kaken Pharmaceutical Co., Ltd.
Collaboration with Seikagaku
Ferring established a licensing agreement with Seikagaku for SI-6603 in 2016, with the aim of commercializing the treatment in the U.S. pending FDA review. This agreement allows Ferring to develop and commercialize the treatment globally, excluding Japan.
Ferring Pharmaceuticals — Who We Are
Founded in 1950 and based in Switzerland, Ferring Pharmaceuticals is a leading global company committed to enhancing patient care. They operate across various medical fields, including reproductive medicine, gastroenterology, and orthopaedics. With over 7,000 employees worldwide, including a significant presence in the U.S., Ferring continuously strives to deliver innovative treatments that improve lives.
Frequently Asked Questions
What is SI-6603?
SI-6603 is an investigational drug designed to relieve radicular leg pain caused by lumbar disc herniation, delivered through a single intradiscal injection.
How effective was SI-6603 in the studies?
The studies demonstrated significant pain relief, with notable improvements seen in measures compared to control groups.
What types of adverse effects were observed in the trials?
Participants reported some treatment-emergent adverse events, with back pain and spinal MRI abnormalities being the most frequently noted issues.
What is lumbar disc herniation?
Lumbar disc herniation occurs when the gel-like center of a spinal disc pushes through its outer layer, which can compress nerves and lead to pain.
Is SI-6603 approved for use in the United States?
SI-6603 is currently under FDA review and has not yet been approved for use in the United States.
